ABSI Absci Corporation - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ABSI Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$2.65
Analyst Target
$8.05
+203.6%
Upside
52W High
$5.23
52W Low
$2.01
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 21, 2026
Market cap
$398.48M
P/E
N/A
ROE
-55.7%
Profit margin
N/A
Debt/Equity
0.03
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ABSI's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. The company exhibits catastrophic profitability metrics, including a -7,977.25% operating margin and negative ROE/ROA, alongside a 77.8% YoY revenue decline. Despite a modest insider sentiment score and a few recent earnings surprises, the bearish insider activity and lack of cash flow or dividend strength undermine confidence. The stock trades at a staggering Price/Sales of 141.56, far exceeding peers and justifying a deep discount given its deteriorating fundamentals.
Key Strengths
Insider sentiment remains moderately positive at 60/100, suggesting some internal confidence
Recent quarterly EPS growth shows a +16.7% Q/Q improvement, indicating potential stabilization
High current and quick ratios (5.89 and 5.17) suggest strong short-term liquidity
Debt/Equity ratio of 0.03 indicates minimal leverage risk
Analyst target price of $8.05 implies a significant upside potential if fundamentals improve
Key Risks
Piotroski F-Score of 1/9 signals severe financial distress and operational failure
Negative operating margin (-7,977.25%) and negative ROE (-55.68%) reflect deep unprofitability
77.8% YoY revenue contraction indicates a failing business model or market rejection
Insider selling of $0.13M in the last 6 months signals bearish sentiment from leadership
Price/Sales of 141.56 is unsustainable for a company with no earnings, growth, or cash flow
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
15
Weak
15
30
20
10
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 1/9, Negative profitability and revenue decline, Lack of cash flow and earnings, High valuation multiple without earnings support, Bearish insider activity
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- Low debt/Equity ratio (0.03)
- High current and quick ratios (5.89, 5.17)
Watchpoints
- No Graham Number or intrinsic value estimate
- Price/Sales of 141.56 is extremely high for a loss-making company
- No P/E or PEG ratios available, indicating no earnings to value
Future
30/100
Ref Growth rates
Positives
- Recent Q/Q EPS growth of +16.7%
- Analyst target price of $8.05 suggests strong upside potential
Watchpoints
- 77.8% YoY revenue decline
- Forward P/E of -3.76 indicates continued losses
- No visible path to sustainable growth
Past
20/100
Ref Historical trends
Positives
- Some quarters beat estimates (e.g., +15.3% surprise in 2023-03-30)
- Historical EPS surprise average of -2.19% over last 4 quarters
Watchpoints
- Consistently negative earnings surprises in most quarters
- 2021-09-07: +13.7% surprise, but followed by massive -94.1% in 2021-11-09
- Long-term 5Y return of -87.7% reflects persistent underperformance
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt/Equity (0.03)
- High current and quick ratios (5.89, 5.17)
Watchpoints
- Piotroski F-Score of 1/9 (extremely weak)
- No Altman Z-Score available, but financial distress is evident
- Negative ROE, ROA, and operating margin
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend Strength: 0/100
- No history of dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.65
Analyst Target
$8.05
Upside/Downside
+203.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ABSI and closest competitors.
Updated 2026-02-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ABSI
Absci Corporation
Primary
|
-87.7% | +9.1% | -48.9% | +0.8% | -12.2% | +3.9% |
|
AQST
Aquestive Therapeutics, Inc.
Peer
|
-42.6% | +262.8% | +3.5% | -21.9% | -45.7% | -2.1% |
|
AGL
agilon health, inc.
Peer
|
-96.8% | -95.0% | -73.1% | -51.9% | +41.4% | -2.8% |
|
AUNA
Auna SA
Peer
|
-41.0% | -41.0% | -30.8% | -9.7% | +21.7% | +22.2% |
|
BNR
Burning Rock Biotech Limited
Peer
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-3.76
PEG Ratio
N/A
P/B Ratio
1.89
P/S Ratio
141.56
EV/Revenue
96.55
EV/EBITDA
-2.58
Market Cap
$398.48M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-7977.25%
Gross Margin
N/A
ROE
-55.68%
ROA
-30.62%
Growth
Revenue and earnings growth rates
Revenue Growth
-77.8%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.03
Low debt
Current Ratio
5.89
Strong
Quick Ratio
5.17
Excellent
Cash/Share
$1.01
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-17
$N/A
2025-11-12
$-0.2
+2.5% surprise
2025-08-12
$-0.24
-15.1% surprise
2025-05-13
$-0.21
+6.0% surprise
Healthcare Sector Comparison
Comparing ABSI against 146 companies in the Healthcare sector
(11 bullish, 60 neutral, 75 bearish)
Return on Equity (ROE)
-55.68%
This Stock
vs
-56.86%
Sector Avg
-2.1%
(Below Avg)
Debt to Equity
0.03
This Stock
vs
2.68
Sector Avg
-98.9%
(Less Debt)
Revenue Growth
-77.8%
This Stock
vs
62.23%
Sector Avg
-225.0%
(Slower)
Current Ratio
5.89
This Stock
vs
3.45
Sector Avg
+70.7%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ABSI
Absci Corporation
|
BEARISH | $398.48M | - | -55.7% | -% | $2.65 | |
|
AQST
Aquestive Therapeutics, Inc.
|
BEARISH | $395.29M | - | -% | -158.9% | $3.24 | |
|
AGL
agilon health, inc.
|
BEARISH | $410.85M | - | -73.3% | -5.2% | $0.99 | |
|
AUNA
Auna SA
|
NEUTRAL | $418.91M | 5.78 | 11.4% | 4.3% | $5.66 | |
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-02 | MCCLAIN SEAN | Chief Executive Officer | Sale | 26,761 | $80,015 |
| 2026-02-02 | JONASSON ZACHARIAH | Chairman of the Board | Sale | 17,496 | $52,313 |
| 2026-01-28 | BEDRICK TODD | Officer | Stock Award | 15,000 | - |
| 2025-12-05 | VAN HOUTEN FRANS | Director | Purchase | 40,000 | $148,800 |
| 2025-09-22 | BEDRICK TODD | Officer | Purchase | 10,000 | $27,000 |
| 2025-09-22 | PANGALOS MENELAS N | Director | Purchase | 95,785 | $254,788 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
7 analysts
HC Wainwright & Co.
2025-12-18
Buy
Buy
Needham
2025-12-12
Buy
Buy
Needham
2025-11-13
Buy
Buy
JP Morgan
2025-10-02
Overweight
Past News Coverage
Recent headlines mentioning ABSI from our newsroom.
Newest → oldest
No matching news yet.